Search bioRxiv⌕ Search

Biology subjects

Bergamini, M.

Publications and source records attributed to Bergamini, M..

2 recordsLinked to original sources

Intrinsic excitability controls structural plasticity of cerebellar climbing fibers

In the cerebellum, climbing fibers (CFs) convey a teaching signal to Purkinje cells (PCs) that is crucial for cerebellar learning. They undergo activity-dependent synaptic plasticity during development and learning, and their transverse branches have an activity-dependent control of mobility. The maintenance of their structure was shown to rely on the growth-associated protein 43 (GAP-43), which is highly expressed in these fibers under basal conditions in adults and which is controlled by intracellular calcium levels and phosphorylation. Although activity-dependent structural plasticity occurs in several axonal fibers throughout the brain, it remains unclear whether this is also the case for the main branches of CFs. Here, we investigate this issue using in vivo knock-down of voltage-gated sodium channels (NaVs) in the CF-generating neurons of the inferior olive, and analyzing CF three-dimensional morphology, density and function of synaptic contacts with PCs. We show that the decrease in intrinsic excitability causes a reduction in the number and length of CF branches and that similar effects are caused by the knockdown of GAP-43, suggesting that GAP-43 may mediate this response. We also show that the retraction of CF fibers is associated with a seemingly compensatory increase in the density of CF synaptic terminals and PC dendritic spines, specifically in the area where PCs receive CF inputs. These plastic modifications are associated with a decrease in paired-pulse ratio and an increase in the kinetics and transferred charge of synaptic currents. Our data show that CFs can undergo activity-dependent structural plasticity changes affecting synaptic transmission and suggest the possibility that they contribute to encoding memories in the cerebellum and, if disrupted, to the pathophysiology of cerebellar diseases.

neuroscience↗

Connexin-36-expressing Gap Junctions in VTA GABA Neurons Sustain Opiate Dependence

Drug dependence is characterized by a switch in motivation wherein a positively reinforcing substance becomes negatively reinforcing. Ventral tegmental area (VTA) GABA neurons form a point of divergence between two double dissociable pathways responsible for these respective motivational states. Here we show that this switch from drug-naive to opiate-dependent and withdrawn (ODW) motivation is contingent upon the gap junction-forming protein, connexin-36 (Cx36), in VTA GABA neurons. Intra-VTA infusions of the Cx36 blocker, mefloquine, in ODW rats resulted in a reversion to a drug-naive motivational state and a loss of opiate withdrawal aversions. Consistent with these data, conditional knockout mice lacking Cx36 in GABA neurons (GAD65-Cre;Cx36fl(CFP)/fl(CFP)) were perpetually drug-naive and never experienced opiate withdrawal aversions. Further, viral-mediated rescue of Cx36 in VTA GABA neurons was sufficient to restore their susceptibility to ODW motivation. Our findings reveal a functional role for VTA gap junctions that has eluded prevailing circuit models of addiction. SignificanceThe motivation to seek drugs can vary depending on prior exposure. For instance, recreational and habitual drug use can stem from a desire to experience the pleasurable or relieving properties of the substance, respectively. Here we identify a subpopulation of midbrain neurons that dictate opiate-seeking motivation via expression of the gap junction protein, connexin-36. We show that connexin-36 expression increases upon opiate dependence and withdrawal. We then demonstrate that this is not merely a correlation, as pharmacological or genetic manipulations that interfere with connexin-36 function prevent the development of opiate dependence in rats and mice. Our results identify gap junctions as a critical node in the pathogenesis of opiate addiction, and a potential new target for substance use disorder pharmacotherapies.

neuroscience↗